Primary (6 months):
The cure rate of 2019‐nCoV, the improvement rate of 2019‐nCoV, the incidence of long‐term adverse outcomes
Secondary (2 weeks):
Duration of fever, duration of respiratory symptoms, duration of hospitalization, number of participant(s) need intensive care, number of participant(s) with acute respiratory distress syndrome, number of participant(s) with extra‐pulmonary complications, including shock, renal failure, multiple organ failure, hemophagocytosis syndrome, et al., number of participant(s) who died during the trial (10 months)